Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
22 Août 2023 - 10:10PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of August 2023
Commission
File Number 001-41231
TC
BIOPHARM (HOLDINGS) PLC
(Translation
of registrant’s name into English)
Maxim 1, 2 Parklands Way
Holytown, Motherwell, ML1 4WR
Scotland, United Kingdom
+44 (0) 141 433 7557
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: |
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ ☐ |
|
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ ☐ |
On
August 7, 2023, TC Biopharm (Holdings) PLC (the “Company”) received notice of conversion into equity of the outstanding amount
of its Convertible Loan Note (the ‘Note’). As a result of this conversion, the Company no longer has any convertible notes
currently outstanding.
On
December 31, 2022, the Company had accounted for the Note as a liability in the amount of $789,214 and, following several phased conversions
since then, that liability has now been converted in its entirety into equity.
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
TC BIOPHARM (HOLDINGS) PLC |
|
|
|
|
By: |
/s/
Martin Thorp |
|
Name: |
Martin Thorp |
|
Title: |
Chief Financial Officer |
|
|
|
Date: August 22, 2023 |
|
|
TC BioPharm (NASDAQ:TCBP)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
TC BioPharm (NASDAQ:TCBP)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024